Postoperative Management of Eosinophilic Chronic Rhinosinusitis with Nasal Polyps: Impact of High-Dose Corticosteroid Nasal Spray

Abstract

Introduction Eosinophilic chronic rhinosinusitis (ECRS) is characterized by an eosinophilic inflammation driven by Th2-type cytokines. Glucocorticosteroids are the most common first-line treatment for ECRS with nasal polyps.

Objective We have evaluated the long-term treatment with double-dose intranasal corticosteroids in refractory ECRS nasal polyps resistant to the conventional dose and assessed the risk of adverse systemic effects

Methods Sixteen subjects were enrolled in this study. All subjects had ECRS after endoscopic sinus surgery that resulted in recurrent mild and moderate nasal polyps and were undergoing a postoperative follow-up application of mometasone furoate at a dose of 2 sprays (100 μg) in each nostril once a day (200 μg). All the patients were prescribed mometasone furoate, administered at a dose of 2 sprays (100 μg) in each nostril twice a day (400 μg) for 6 months.

Results The average scores of the symptoms during the regular dose of intranasal steroid treatment were 5.2 ± 2.2, but 6 months after the high-dose application, they had significantly decreased to 2.5 ± 1.4 (p < 0.05). The polyp size showed an average score of 1.38 during the regular dose which was significantly reduced to 0.43 (p < 0.01) by the double dose. Glycated hemoglobin (HbA1c) showed normal ranges in all the patients tested. The cortisol plasma concentration was also normal.

Conclusion Doubling the dose of the nasal topical spray mometasone furoate might be recommended for the treatment of recurrent nasal polyps in the postoperative follow-up of intractable ECRS.

Keywords

chronic rhinosinusitis nasal polyps - adverse effects - intranasal administration - corticosteroids

• References

• 1 Benninger MS, Ferguson BJ, Hadley JA. , et al. Adult chronic rhinosinusitis: definitions, diagnosis, epidemiology, and pathophysiology. Otolaryngol Head Neck Surg 2003; 129 (3, Suppl): S1-S32
• 2 Kaliner MA, Osguthorpe JD, Fireman P. , et al. Sinusitis: bench to bedside. Current findings, future directions. J Allergy Clin Immunol 1997; 99 (6 Pt 3): S829-S848
• 3 Hamilos DL, Leung DYM, Wood R. , et al. Chronic hyperplastic sinusitis: association of tissue eosinophilia with mRNA expression of granulocyte-macrophage colony-stimulating factor and interleukin-3. J Allergy Clin Immunol 1993; 92 (1 Pt 1): 39-48
• 4 Dinis PB, Gomes A. Sinusitis and asthma: how do they interrelate in sinus surgery?. Am J Rhinol 1997; 11 (06) 421-428
• 5 Van Zele T, Claeys S, Gevaert P. , et al. Differentiation of chronic sinus diseases by measurement of inflammatory mediators. Allergy 2006; 61 (11) 1280-1289
• 6 Mygind N, Lildholdt T. Nasal polyps treatment: medical management. Allergy Asthma Proc 1996; 17 (05) 275-282
• 7 Badia L, Lund V. Topical corticosteroids in nasal polyposis. Drugs 2001; 61 (05) 573-578
• 8 Fokkens W, Lund V, Mullol J. ; European Position Paper on Rhinosinusitis and Nasal Polyps Group. EP3OS 2007: European position paper on rhinosinusitis and nasal polyps 2007. A summary for otorhinolaryngologists. Rhinology 2007; 45 (2, suppl. 20): 97-101
• 9 Stjärne P, Olsson P, Alenius M. Use of mometasone furoate to prevent polyp relapse after endoscopic sinus surgery. Arch Otolaryngol Head Neck Surg 2009; 135 (03) 296-302
• 10 Dingsør G, Kramer J, Olsholt R, Søderstrøm T. Flunisolide nasal spray 0.025% in the prophylactic treatment of nasal polyposis after polypectomy. A randomized, double blind, parallel, placebo controlled study. Rhinology 1985; 23 (01) 49-58
• 11 Hissaria P, Smith W, Wormald PJ. , et al. Short course of systemic corticosteroids in sinonasal polyposis: a double-blind, randomized, placebo-controlled trial with evaluation of outcome measures. J Allergy Clin Immunol 2006; 118 (01) 128-133
• 12 Walsh LJ, Lewis SA, Wong CA. , et al. The impact of oral corticosteroid use on bone mineral density and vertebral fracture. Am J Respir Crit Care Med 2002; 166 (05) 691-695
• 13 Tokunaga T, Sakashita M, Haruna T. , et al. Novel scoring system and algorithm for classifying chronic rhinosinusitis: the JESREC Study. Allergy 2015; 70 (08) 995-1003
• 14 Ikeda K, Kondo Y, Sunose H. , et al. Subjective and objective evaluation in endoscopic sinus surgery. Am J Rhinol 1996; 10: 217-220
• 15 Benítez P, Alobid I, de Haro J. , et al. A short course of oral prednisone followed by intranasal budesonide is an effective treatment of severe nasal polyps. Laryngoscope 2006; 116 (05) 770-775
• 16 Stjärne P, Blomgren K, Cayé-Thomasen P, Salo S, Søderstrøm T. The efficacy and safety of once-daily mometasone furoate nasal spray in nasal polyposis: a randomized, double-blind, placebo-controlled study. Acta Otolaryngol 2006; 126 (06) 606-612
• 17 Powell H, Gibson PG. Inhaled corticosteroid doses in asthma: an evidence-based approach. Med J Aust 2003; 178 (05) 223-225
• 18 Cave A, Arlett P, Lee E. Inhaled and nasal corticosteroids: factors affecting the risks of systemic adverse effects. Pharmacol Ther 1999; 83 (03) 153-179
• 19 Holm AF, Fokkens WJ, Godthelp T, Mulder PG, Vroom TM, Rijntjes E. A 1-year placebo-controlled study of intranasal fluticasone propionate aqueous nasal spray in patients with perennial allergic rhinitis: a safety and biopsy study. Clin Otolaryngol Allied Sci 1998; 23 (01) 69-73
• 20 Licata AA. Systemic effects of fluticasone nasal spray: report of 2 cases. Endocr Pract 2005; 11 (03) 194-196
• 21 Vernon HJ, Lane AT, Weston W. Comparison of mometasone furoate 0.1% cream and hydrocortisone 1.0% cream in the treatment of childhood atopic dermatitis. J Am Acad Dermatol 1991; 24 (04) 603-607
• 22 Mösges R, Bachert C, Rudack C. , et al. Efficacy and safety of mometasone furoate nasal spray in the treatment of chronic rhinosinusitis. Adv Ther 2011; 28 (03) 238-249
• 23 Bruni FM, De Luca G, Venturoli V, Boner AL. Intranasal corticosteroids and adrenal suppression. Neuroimmunomodulation 2009; 16 (05) 353-362